Share Email Print
cover

Proceedings Paper

Tumor-specific fluorescent contrast agents
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Several dyes are currently used for various biomedical applications due to their biocompatibility and high molar absorptivity. Localization of dyes in tumors may be mediated by several factors such as leaky vasculature and high metabolic activity in proliferating cells. However, these mechanisms of action make it difficult to differentiate inflammation from benign or malignant tumors. In order to enhance their tumor specificity, dyes have been conjugated to biomolecules that target unique factors in various diseased state. However, such large biomolecules can elicit adverse immunogenic reactions in humans, and are often preferentially taken up by the liver. Furthermore, for solid tumors which may rely on diffusion of the biomarkers from the vascular, penetration of large dye conjugates is not favorable. To overcome these problems, we designed and synthesized novel dye-peptide conjugates that are receptor specific. The efficacy of these new fluorescent contrast agents was tested in vivo in well-characterized rat tumor lines. The resulting optical images demonstrate that successful specific tumor targeting was achieved.

Paper Details

Date Published: 19 April 2000
PDF: 7 pages
Proc. SPIE 3917, Optical Biopsy III, (19 April 2000); doi: 10.1117/12.382718
Show Author Affiliations
Samuel I. Achilefu, Mallinckrodt Inc. (United States)
Richard B. Dorshow, Mallinckrodt Inc. (United States)
Joseph E. Bugaj, Mallinckrodt Inc. (United States)
Raghavan Rajagopalan, Mallinckrodt Inc. (United States)


Published in SPIE Proceedings Vol. 3917:
Optical Biopsy III
Robert R. Alfano, Editor(s)

© SPIE. Terms of Use
Back to Top